Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 109.51% | Wells Fargo | → $1 | Downgrades | Overweight → Equal-Weight |
| 11/03/2023 | 319.02% | RBC Capital | $6 → $2 | Downgrades | Outperform → Sector Perform |
| 08/15/2023 | 1366.58% | Truist Securities | $8 → $7 | Maintains | Buy |
| 08/14/2023 | 947.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 1995.12% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 738.05% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 1785.61% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 1157.07% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 1576.09% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 947.56% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 214.27% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 3042.68% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 3252.19% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 2623.65% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 3042.68% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 4090.24% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 947.56% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 3880.72% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 4509.26% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 3252.19% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 5137.8% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 4090.24% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 4509.26% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 2833.17% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 2204.63% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 2204.63% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 109.51% | 富國銀行 | → 1 美元 | 降級 | 超重 → 重量相等 |
| 11/03/2023 | 319.02% | 加拿大皇家銀行資本 | 6 美元 → 2 美元 | 降級 | 跑贏大盤 → 行業表現 |
| 08/15/2023 | 1366.58% | Truist 證券 | 8 美元 → 7 美元 | 維護 | 買 |
| 08/14/2023 | 947.56% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 08/11/2023 | 1995.12% | Wedbush | 16 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 08/10/2023 | 738.05% | 富國銀行 | 5 美元 → 4 美元 | 維護 | 超重 |
| 08/09/2023 | 1785.61% | 巴克萊 | 11 美元 → 9 美元 | 維護 | 超重 |
| 08/09/2023 | 1157.07% | 加拿大皇家銀行資本 | 8 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 05/10/2023 | 1576.09% | Truist 證券 | 16 美元 → 8 美元 | 維護 | 買 |
| 05/01/2023 | 947.56% | HC Wainwright & Co. | 15 美元 → 5 美元 | 維護 | 買 |
| 04/28/2023 | 214.27% | B of A 類證券 | 5 美元 → 1.5 美元 | 降級 | 中性 → 跑贏大盤 |
| 03/03/2023 | 3042.68% | HC Wainwright & Co. | 25 美元 → 15 美元 | 維護 | 買 |
| 02/27/2023 | 3252.19% | Wedbush | → 16 美元 | 升級 | 中性 → 跑贏大盤 |
| 02/23/2023 | 2623.65% | 加拿大皇家銀行資本 | 22 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 2023 年 4 月 1 日 | 3042.68% | 富國銀行 | 20 美元 → 15 美元 | 維護 | 超重 |
| 2022 年 7 月 11 日 | 4090.24% | 富國銀行 | 22 美元 → 20 美元 | 維護 | 超重 |
| 06/13/2022 | 947.56% | Wedbush | → 5 美元 | 假設 | → 中立 |
| 2022 年 5 月 4 日 | 3880.72% | Truist 證券 | 23 美元 → 19 美元 | 維護 | 買 |
| 2021 年 4 月 5 日 | 4509.26% | 加拿大皇家銀行資本 | → 22 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 01/06/2021 | 3252.19% | Stifel | → 16 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 2020 年 12 月 16 日 | 5137.8% | HC Wainwright & Co. | → 25 美元 | 假設 | → 購買 |
| 2020 年 8 月 9 日 | 4090.24% | B of A 類證券 | → 20 美元 | 恢復 | → 購買 |
| 07/07/2020 | 4509.26% | SunTrust 羅賓遜·漢弗萊 | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 6 月 22 日 | 2833.17% | HC Wainwright & Co. | 16 美元 → 14 美元 | 維護 | 買 |
| 11/14/2018 | 2204.63% | 摩根大通 | 35 美元 → 11 美元 | 維護 | 中立 |
| 11/14/2018 | 2204.63% | 摩根大通 | 35 美元 → 11 美元 | 降級 | 超重 → 中性 |
| 11/09/2018 | — | 古根海姆 | 降級 | 買入 → 中性 |
What is the target price for Sangamo Therapeutics (SGMO)?
Sangamo Therapeutics（SGMO）的目標價格是多少？
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Wells Fargo on November 6, 2023. The analyst firm set a price target for $1.00 expecting SGMO to rise to within 12 months (a possible 109.51% upside). 16 analyst firms have reported ratings in the last year.
富國銀行於2023年11月6日公佈了Sangamo Therapeutics（納斯達克股票代碼：SGMO）的最新目標股價。該分析公司將目標股價定爲1.00美元，預計SGMO將在12個月內升至12個月內（可能上漲109.51％）。去年有16家分析公司公佈了評級。
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
分析師對Sangamo Therapeutics（SGMO）的最新評級是多少？
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Wells Fargo, and Sangamo Therapeutics downgraded their equal-weight rating.
富國銀行對Sangamo Therapeutics（納斯達克股票代碼：SGMO）的最新分析師評級由富國銀行提供，Sangamo Therapeutics下調了其同等權重評級。
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Sangamo Therapeutics（SGMO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Sangamo Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Sangamo Therapeutics的最新評級是在2023年11月6日公佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
分析師對 Sangamo Therapeutics (SGMO) 的評級正確嗎？
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a downgraded with a price target of $0.00 to $1.00. The current price Sangamo Therapeutics (SGMO) is trading at is $0.48, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Sangamo Therapeutics（SGMO）評級已下調，目標股價爲0.00美元至1.00美元。Sangamo Therapeutics（SGMO）目前的交易價格爲0.48美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。